May 14, 2020
Cellphire Announces Orphan Drug Designation of Thrombosomes® for Treatment of Acute Radiation Syndrome
Dec 06, 2019
Enzychem Lifesciences announces collaborative Material Transfer Agreement (MTA) with the Armed Forces Radiobiology Research Institute (AFRRI) for the Development of a Radiation Medical Countermeasure.
Aug 27, 2019
Chrysalis BioTherapeutics Receives BARDA Contract for Over $10 million
Aug 21, 2019
Chrysalis BioTherapeutics Granted Orphan Drug Status for TP508
Aug 08, 2019
Radiation levels normal after explosion at Russian military base: defence ministry
Jul 29, 2019
Soligenix Receives European Patents for Oral BDP in the Treatment of Acute Radiation Injury of the Gastrointestinal Tract
Jun 12, 2019
Bolder BioTechnology Announces FDA Orphan Drug Designation for BBT-059 for Acute Radiation Syndrome
Apr 05, 2019
Medical Radiation Shielding Market to Attain a Value of US$1,100 Million by 2022, Says TMR
Oct 24, 2018
Bolder BioTechnology to Present Preclinical Data for Three Research Programs at Acute Radiation Syndrome Meeting
Sep 06, 2018
Bolder BioTechnology Announces Presentation at Radiation Injury Treatment Conference
Jun 06, 2018
Partner Therapeutics (PTx) Announces US FDA Approval of Leukine® (sargramostim) for the Treatment of Acute Radiation Syndrome
Jan 19, 2018
Enzychem Lifesciences announces the FDA Orphan Drug Designation granted to EC-18 on Acute Radiation Syndrome (ARS)
Dec 14, 2017
Low-Dose Radiation Can Enhance Natural Barriers to Cancer, according to the Journal of American Physicians and Surgeons